Biomarkers of Immunotoxicity for Environmental and Public Health Research

被引:38
作者
Duramad, Paurene [2 ]
Holland, Nina T. [1 ]
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
关键词
asthma; COPD; biomarker validation; immunoinformatics; Luminex; immunome; immunotoxicity; SURROGATE END-POINTS; OBSTRUCTIVE PULMONARY-DISEASE; CELL CYTOKINE PROFILES; SERUM IMMUNOGLOBULIN-E; CLINICAL-TRIALS; INDUCED SPUTUM; IMMUNOLOGICAL BIOMARKERS; VALIDATION CRITERIA; HIERARCHICAL LEVELS; PROTEOMIC PATTERNS;
D O I
10.3390/ijerph8051388
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
The immune response plays an important role in the pathophysiology of numerous diseases including asthma, autoimmunity and cancer. Application of biomarkers of immunotoxicity in epidemiology studies and human clinical trials can improve our understanding of the mechanisms that underlie the associations between environmental exposures and development of these immune-mediated diseases. Immunological biomarkers currently used in environmental health studies include detection of key components of innate and adaptive immunity (e. g., complement, immunoglobulin and cell subsets) as well as functional responses and activation of key immune cells. The use of high-throughput assays, including flow cytometry, Luminex, and Multi-spot cytokine detection methods can further provide quantitative analysis of immune effects. Due to the complexity and redundancy of the immune response, an integrated assessment of several components of the immune responses is needed. The rapidly expanding field of immunoinformatics will also aid in the synthesis of the vast amount of data being generated. This review discusses and provides examples of how the identification and development of immunological biomarkers for use in studies of environmental exposures and immune-mediated disorders can be achieved.
引用
收藏
页码:1388 / 1401
页数:14
相关论文
共 78 条
[1]   The biomarkers consortium: On the critical path of drug discovery [J].
Altar, C. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :361-364
[2]  
[Anonymous], BIOSTATISTICS
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments [J].
Baggerly, KA ;
Morris, JS ;
Coombes, KR .
BIOINFORMATICS, 2004, 20 (05) :777-U710
[5]   Toxicogenomics in the assessment of immunotoxicity [J].
Baken, Kirsten A. ;
Vandebriel, Rob J. ;
Pennings, Jeroen L. A. ;
Kleinjans, Jos C. ;
van Loveren, Henk .
METHODS, 2007, 41 (01) :132-141
[6]   In biomarkers we trust? [J].
Baker, M .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :297-304
[7]   A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E [J].
Baldini, M ;
Lohman, IC ;
Halonen, M ;
Erickson, RP ;
Holt, PG ;
Martinez, FD .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1999, 20 (05) :976-983
[8]  
BANERJI U, 2008, CLIN CANC RES, V14
[9]   The role of lymphocytes in the pathogenesis of asthma and COPD [J].
Baraldo, Simonetta ;
Oliani, Kim Lokar ;
Turato, Graziella ;
Zuin, Renzo ;
Saetta, Marina .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (21) :2250-2256
[10]   Immunology of asthma and chronic obstructive pulmonary disease [J].
Barnes, Peter J. .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (03) :183-192